One key piece of information contained in the pathology ... To summarize, being HER2-positive can mean more treatment options, even though your cancer is aggressive. Yet just because your breast ...

If your cancer is also hormone receptor-positive, meaning that it needs the ... What is the life expectancy of a HER2-positive breast cancer patient? Life expectancy varies based on the cancer ...

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't ...

Patients with a type of breast cancer called HER2-positive are less likely to survive ... had residual disease after neoadjuvant treatment. Information on the amount of residual disease ('residual ...

Patients with HER2-positive breast cancer that has started ... to be able to control the disease for several years." More information: Presentation: Updated overall survival (OS) outcomes from ...

Prior to DESTINY-Breast06, the randomized phase 3 DESTINY-Breast04 trial showed trastuzumab deruxtecan prolonged PFS and OS in patients with HER2-low unresectable and/or metastatic breast cancer ...

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

The prescribing information for Ziihera also includes ... therapy vs SOC therapy alone in the first-line setting for patients with HER2-positive BTC, will serve as the confirmatory trial for ...

The Phase 1 clinical trial, currently taking place in Australia, is designed to evaluate the safety, tolerability, and preliminary efficacy of AP402 in HER2+ patients with advanced solid tumors ...

“The dosing of the first patient in this trial is a significant achievement in our efforts to find new treatment options for patients with HER2-positive breast cancer that continues to progress ...